Inhalational compound anaesthetic agent

Abstract

The invention provides an inhalational compound anaesthetic agent. The inhalational compound anaesthetic agent is characterized by comprising an A agent and a B agent, wherein the A agent serves as an inducer and comprises nitrous oxide, sodium chloride, perfume and a compound emulgator; the B agent serves as an anesthesia retaining agent and comprises flos daturae, radix aconiti agrestis, sevoflurane, sodium chloride, perfume and a compound emulgator; according to the A agent, the content of nitrous oxide is 1-5%, the content of the compound emulgator is 15-25%, and the content of the perfume is 0.1-0.3%; according to the B agent, the content of flos daturae is 0.5-0.9g / 100mL, the content of radix aconiti agrestis is 0.1-0.5g / 100mL, and the content of the sevoflurane is 1.5-2.5%, the content of the compound emulgator is 10-20%, and the content of the perfume is 0.1-0.3%. The inhalational compound anaesthetic agent is simple to operate during use; the A agent can be used for quickly inducing anesthesia and can be directly inhaled by an inhaling device; the B agent is used for retaining anesthesia, can be inhaled by a matched anesthesia machine and can also be infused into the body by other manners; the infusing time and dosage can be flexibly arranged according to the needs of the operation; and the inhalational compound anaesthetic agent can be applied to complex or long-time operation.

Description

technical field [0001] The invention relates to an inhalation anesthetic and its inhalation device. Background technique [0002] Administration of general anesthesia can produce considerable adverse side effects. In general inhalation anesthesia, the anesthesia tube must be placed in the trachea of ​​the human body, and vomiting must be prevented, which often leads to upper respiratory tract injury of the patient. Statistically, many patients experience hoarseness and tenderness in the mouth and throat after surgery. Currently, the doses required for anesthetics to reach target neural organs may have adverse effects on non-target organs, especially the heart, where the risk of cardiopulmonary morbidity is greatly increased during general anesthesia, especially in the elderly, with substantial long-term cognitive impairment following general anesthesia Evidence for (Moller et al., 1988, Lancet., 351:857-861). In addition, overall morbidity and mortality from cardiorespira...

AI Technical Summary

Problems solved by technology

[0003] The purpose of the present invention is to solve the problems in the above-mentioned prior art and to develop an inhaled compound anesthetic in combination with the clinical needs of anesthesia. By emulsifying nitrous oxide, Several kinds of drugs such as Dajinhua, Aconitum, and Sevoflurane are scientifically formulated to achieve a reasonable and good anesthesia effect, and at the same time minimize the side effects of each single drug, overcoming the complexity of common inhalational anesthesia operations, expensive costs, and poor equipment. High technical requirements, difficult to control the depth and maintenance time of anesthesia by intramuscular injection, easy to produce obvious respiratory and circulatory system effects, difficult to apply to complex and long-term surgery and other technical problems